Oncology News | pharmaphorum

News

Amgen grabs EU approval for pathfinder KRAS drug Lumykras

Amgen now has regulatory approval on both sides of the Atlantic for Lumykras, the culmination of many years of effort to bring a drug to market that inhibits KRAS – a cancer target that for

News

Roivant joins RNA splicing push with Eisai deal

Roivant is the latest pharma group to take a position in the emerging field of therapies targeted at RNA splicing, licensing exclusive rights to a drug developed by a unit of Japanese drugm

News

FDA gives AbbVie's c-Met lung cancer ADC a breakthrough tag

The FDA thinks an antibody-drug conjugate (ADC) developed by AbbVie could set new standards in treatment for certain patients with lung cancer, awarding the drug breakthrough status.

News

Janssen J&J Johnson and Johnson pharmaceutical companies

J&J goes after another FDA approval for a cancer bispecific

Johnson & Johnson's much-touted crop of bispecific antibodies for cancer generated its first commercial product in May, and the drugmaker has now filed for FDA approval of a second cand

News

FDA gives Daiichi Sankyo's HER3 drug a breakthrough tag

Daiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody-drug conjugate (ADC) in clinical trials for lung cancer.

News